White Paper: Add Consistency to Monoclonal Gammopathy Testing: N Latex FLC kappa and lambda Assays

Monoclonal gammopathies range from asymptomatic, premalignant monoclonal gammopathy of undetermined significance (MGUS) to life-threatening manifestations such as light chain amyloidosis or fast-progressing multiple myeloma requiring highly aggressive therapy.

Some years ago, the diagnosis of monoclonal gammopathies was based on the finding of an elevated level of a complete immunoglobulin. However, there are a substantial number of monoclonal gammopathies in which no increased expression of intact immunoglobulin molecules is seen, but rather increased levels of either the free light chain (FLC) kappa or lambda, resulting in an abnormally low or high FLC kappa/lambda ratio.

Learn more about innovative FLC methods based on monoclonal antibodies.

Complete the form below to receive the white paper and learn more about the advantages of N Latex FLC kappa and lambda Assays.



Because of some maintenance activities, this service is not available currently.
Please try again later.

An issue occurred on this form. Either, one or more missing and/or incorrect entries are in the form. Each is underlined in red. Or, the data inserted by you seems to be invalid. Please check if you filled in all form fields as expected according to the field names (e.g. ‘First Name’, ‘Last Name’ etc.). Please correct and re-submit your request again. Thank you!

An issue occurred on this form. The data inserted by you seems to be invalid. Please check if you filled in all form fields as expected according to the field names (e.g. ‘First Name’, ‘Last Name’ etc.). Please correct and re-submit your request again. Thank you!

What best describes your current situation?

 

* Required

Thank you for your interest in Siemens Healthineers. Click the link below to access and download the document you requested:

Add Consistency to Monoclonal Gammopathy Testing: N Latex FLC kappa and lambda Assays

Due to technical reasons your request cannot be completed. Please try again or contact us. We apologize for the inconvenience caused.


Share this page: